| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
CASI Pharmaceuticals, Inc.
13D/A
CASIF · G1933S101
|
58.8% |
5/18/2026
Event 5/18/2026
|
||||
| WEI-WU HE, Ph.D. | 58.8% | |||||
| Huiying Memorial Foundation | 3.1% | |||||
| Emerging Technology Partners, LLC | 52.0% | |||||
| ETP Global Fund L.P. | 3.7% | |||||
| Etp Biohealth III Fund, L.P. | 1.5% | |||||
| HE Family GRAT | 0.5% | |||||
| ETP Global III Fund L.P. | 49.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.